Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
Portfolio Pulse from Benzinga Newsdesk
Trevena, Inc. (NASDAQ:TRVN) has completed the initial analysis of OLINVYK continuous respiratory monitoring data from the VOLITION study. The study assessed the potential impact of OLINVYK on respiratory, gastrointestinal (GI), and cognitive function outcomes in the postoperative setting.
October 02, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Trevena's completion of the initial analysis of OLINVYK data from the VOLITION study could potentially impact the company's stock positively if the results are favorable.
The completion of the initial analysis of OLINVYK data from the VOLITION study is a significant milestone for Trevena. If the results are positive, it could potentially lead to increased investor confidence and a rise in the company's stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100